{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T22:58:14Z","timestamp":1776034694183,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejim.2023.11.019","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T19:54:15Z","timestamp":1701546855000},"page":"102-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Features of immune mediated diseases in JAK2 (V617F)-positive myeloproliferative neoplasms and the potential therapeutic role of JAK inhibitors"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4840-7961","authenticated-orcid":false,"given":"Carmen","family":"\u00c1lvarez-Reguera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8565-2985","authenticated-orcid":false,"given":"Diana","family":"Prieto-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5690-5330","authenticated-orcid":false,"given":"Alba","family":"Herrero-Morant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"S\u00e1nchez-Bilbao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Batlle-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Fern\u00e1ndez-Luis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerea","family":"Paz-Gandiaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2023.11.019_bib0001","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ejim.2023.11.019_bib0002","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.11.019_bib0003","first-page":"83","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview","volume":"102","author":"Sabattini","year":"2010","journal-title":"Pathologica"},{"key":"10.1016\/j.ejim.2023.11.019_bib0004","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2023.11.019_bib0005","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3390\/cells8080854","article-title":"Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation","volume":"8","author":"Perner","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejim.2023.11.019_bib0006","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.3390\/ijms23063206","article-title":"Thromboinflammation in myeloproliferative neoplasms (MPN)-A puzzle still to be solved","volume":"23","author":"Bhuria","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejim.2023.11.019_bib0007","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population","volume":"96","author":"Nielsen","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.ejim.2023.11.019_bib0008","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/102476","article-title":"MPNs as inflammatory diseases: the evidence, consequences, and perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.ejim.2023.11.019_bib0009","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ejim.2023.11.019_bib0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.20161228","article-title":"Autoinflammatory periodic fever, immunodeficiency, and thrombocytopenia (PFIT) caused by mutation in actin-regulatory gene WDR1","volume":"214","author":"Standing","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejim.2023.11.019_bib0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.55563\/clinexprheumatol\/ddxmp9","article-title":"Myeloid neoplasms and autoimmune diseases: markers of association","volume":"40","author":"Galimberti","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejim.2023.11.019_bib0012","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s10067-020-05286-y","article-title":"The relationship between JAK2(V617F) mutation and dermatomyositis-a case report and literature review","volume":"40","author":"Xu","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2023.11.019_bib0013","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.59","article-title":"Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia","volume":"30","author":"Gunnarsson","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2023.11.019_bib0014","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","article-title":"An immune dysregulation in MPN","volume":"9","author":"Barosi","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"Suppl 112","key":"10.1016\/j.ejim.2023.11.019_bib0015","first-page":"234","article-title":"Primary myelofibrosis but not autoimmune myelofibrosis accompanied by Sj\u00f6gren's syndrome and primary biliary cirrhosis in a patient with trisomy 8 mosaic: a case report and literature review","volume":"36","author":"Lu","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejim.2023.11.019_bib0016","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/eji.202048922","article-title":"Ten years after","volume":"51","author":"Spinelli","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ejim.2023.11.019_bib0017","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/bjh.17850","article-title":"The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy","volume":"196","author":"Strickland","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2023.11.019_bib0018","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejim.2023.11.019_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2022-222335","article-title":"Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus","author":"D\u00f6rner","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2023.11.019_bib0020","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3390\/ph15080936","article-title":"JAK inhibitors for treatment of autoimmune diseases: lessons from systemic sclerosis and systemic lupus erythematosus","volume":"15","author":"Kotyla","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejim.2023.11.019_bib0021","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s10753-020-01322-w","article-title":"Inhibition of JAK-STAT signaling by baricitinib reduces interferon-\u03b3-induced CXCL10 production in human salivary gland ductal cells","volume":"44","author":"Aota","year":"2021","journal-title":"Inflammation"},{"key":"10.1016\/j.ejim.2023.11.019_bib0022","doi-asserted-by":"crossref","first-page":"e15437","DOI":"10.1111\/dth.15437","article-title":"Janus kinase inhibitors for treatment of morphea and systemic sclerosis: a literature review","volume":"35","author":"McGaugh","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejim.2023.11.019_bib0023","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1111\/jdv.14876","article-title":"The use of JAK inhibitors in the treatment of progressive systemic sclerosis","volume":"32","author":"Deverapalli","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejim.2023.11.019_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103168","article-title":"JAK inhibitors and systemic sclerosis: a systematic review of the literature","volume":"21","author":"Moriana","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejim.2023.11.019_bib0025","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/hxin6o","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","author":"Paik","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejim.2023.11.019_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.881705","article-title":"Perspectives of JAK inhibitors for large vessel vasculitis","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejim.2023.11.019_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221093211","article-title":"Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review","volume":"14","author":"\u00c1lvarez-Reguera","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523004168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523004168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T18:59:27Z","timestamp":1715108367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523004168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":27,"alternative-id":["S0953620523004168"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.11.019","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Features of immune mediated diseases in JAK2 (V617F)-positive myeloproliferative neoplasms and the potential therapeutic role of JAK inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}